After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | The company doubled sales of its Biogen-partnered Alzheimer's disease treatment during its 2025 fiscal year.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift…
Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is making…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
